Telehealth Giant Hims & Hers Partners with Eli Lilly for Direct Weight Loss Drug Delivery
Eli Lilly partners with Hims & Hers to offer Zepbound and Foundayo directly to telehealth patients with self-pay options starting at $149.
Stocks · News reference
Hims & Hers Launches Injectable and Oral Testosterone Treatments
Hims & Hers has expanded its men's health program by introducing new injectable and oral testosterone treatment options.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Eli Lilly and Hims & Hers Announce Agreement to Expand Access to Obesity Medications
Hims & Hers Health, Inc. and Eli Lilly and Company have entered into an agreement to provide patients on the Hims & Hers platform access to Lilly's obesity medications, Zepbound and Foundayo.
HIMS 5-DAY DEADLINE ALERT: Hims & Hers Health Investors with Significant Losses Encouraged to Contact Hagens Berman Before Nov. 2, 2026 Deadline in Securities Class Action
Hims & Hers Health faces a securities class action lawsuit following an FTC complaint alleging deceptive health data sharing with third-party advertising platforms and ROSCA violations related to subscription billing practices. The company's stock plunged 14.7% on July 29, 2026, erasing over $970 million in market value. Investors with substantial losses are urged to submit claims before the November 2, 2026 deadline.
Hims & Hers Health, Inc. Files Motion to Dismiss FTC Complaint
Hims & Hers Health, Inc. has formally requested that a judge dismiss the complaint filed against the company by the Federal Trade Commission.
'Hims Seeks Dismissal of FTC Suit Over User Data, Subscriptions' - Bloomberg News
Hims Launches Injectable And Oral Testosterone Replacement Therapies